|
Overview | Short
Courses | Day 1 |
Day 2 | Download Brochure
DAY ONE
THURSDAY, JANUARY 15
7:00 am – 3:00 pm Conference Registration
7:30 Breakfast Workshop (Sponsorship
Available)
DISCOVERING THE POSSIBILITIES – TOOLS
8:15 Chairperson’s Remarks
8:25 Featured Presentation
Development
of Targeted Proteomic Analysis using MRM-MS for Identification of Diagnostic
Protein Biomarkers
Daniel
Martin, Ph.D., Assistant Professor, Research, Institute for Systems Biology
9:05
Speaker to be Announced
9:35 Cancer Diagnostics and Prognostics Using Protein Networks and Mass Spectrometry
Han-Yu Chuang, Ph.D. Candidate, Trey Ideker’s Laboratory, Bioinformatics, University of California, San Diego
We have proposed a novel approach to integrate gene expression with protein interactions to dissect breast cancer metastasis. The new prognostic markers predict the risk of metastasis more accurately than previous approaches based only on gene expression. More than being more reproducible and robust, our subnetworks give molecular models for how these markers might be associated within disease pathways. Currently we are extending this network-based analysis to unveil the mechanisms underlying the progression of Chronic Lymphocytic Leukemia by using not only gene expression from microarrays but also protein expression from mass spectrometry.
10:05 Coffee Break in the Exhibit Hall
11:00 Epitope Mapping with Saturation Mutagenesis: A Case-Study of Single-Chain, Conformation-Sensitive Antibodies to the Erythropoietin Receptor
Christopher Mehlin, Ph.D., Senior Scientist, Protein Science, Amgen
The determination of where an antibody binds on its antigen is the subject of a considerable amount of interest but no real methodological consensus. Peptide-based techniques are frequently employed in mapping studies, but when the epitopes have conformational requirements or span regions which are distant in linear sequence then approaches which rely on linear peptides typically fail. Presented here are a set of modeling, cloning, and assay techniques optimized to generate a high-throughput scanning mutagenesis platform with wide applicability to epitope mapping programs. Epitope mapping results are presented for a panel of conformation-sensitive, single-chain antibodies against the erythropoietin receptor (EpoR). Exhaustive alanine scanning of the receptor surface was combined with a selected set of arginine mutations and competition experiments to provide a relatively complete picture of the epitopes involved. A major benefit of this technique is that large numbers of different antibody candidates can be mapped at high resolution in parallel.
11:30 Panel Discussion with Morning Speakers
12:00 pm Close of Morning Session
12:15 Luncheon Workshop (Sponsorship Available) or
Lunch on Your Own
VALIDATING THE POSSIBILITIES - ASSAYS
1:45 Chairperson’s Remarks
Nigel Clarke, Ph.D., Director, Core Mass Spectrometry Lab, Quest
Diagnostics Nichols Institute
1:50 Raising the Bar - NCI’s Antibody Characterization Pipeline
Henry Rodriguez, Ph.D., M.B.A., Director, Clinical Proteomic Technologies for Cancer, Office of Technology and Industrial Relations, NCI/NIH
One of the most significant roadblocks of diagnostic techniques is a lack of high quality and well characterized protein affinity capture reagents (antibodies). This barrier was recognized by the NCI, which led to the development of an antibody characterization pipeline, as part of the Reagents and Resources component of its Clinical Proteomic Technologies for Cancer initiative. At present, over 80 cancer-related antigens have been selected with partnerships involved in the antigen production, antibody production/characterization and distribution. This program acts as a catalyst to spur the development of pivotal resources (such as antibodies) that serves the research community, public and private entities, and international collaborations, needed to accelerate biomarker discovery and validation, translational research, molecular diagnostics, and therapeutic monitoring.
2:20 Using a Combination of Genomics and Proteomics Technologies to Understand the Broad Pharmacological Effect of Inhibition of Cancer Target
Yuxin Wang, Ph.D., Senior Research Scientist, Translational Medicine, Pfizer
Small interfering RNAs (siRNAs) have been widely exploited for sequence-specific gene knockdown and hold promise as therapeutic agents. However, off-target gene silencing can have significant impact on siRNA drug discovery. Therefore, the development of reliable protocols for identifying on/off-target effect is essential for siRNA-related studies. This talk focuses on introducing state-of-the-art methodology used to identify drug on/off-target effect via gene microarray-based gene expression profiling and antibody array-based protein expression profiling.
2:50 Profiling
Serum Antibodies To Tumor Antigens
Henry
Hepburne-Scott, Ph.D., Vice President, Business Development, Serametrix
Serametrix’s assay for multiplex detection
of serum antibodies uses a proprietary array of tumor antigens. The
full-length recombinant proteins on our arrays were all selected according to
specific criteria - all are associated with cancer, have demonstrated
immunogenicity and have strong potential as biomarkers for drug discovery and
development. We have been using this array to profile the serum of patients
receiving novel cancer therapies in clinical trials. Comparisons between pre-
and post-treatment patients, and between non-responders and responders, reveal
differences in the humoral immune status with respect to key tumor antigens.
Data from such studies can help to monitor immune response to drugs, give
early warning of immune-related adverse events and even provide a high value
companion diagnostic to identify responders in pre-treatment cohorts.
|
3:20 96-Well Multiplexed Protein System Using Novel
Colorimetric Detection
Bryce Nelson, Ph.D., Vice President, Research and Development, Gentel Biosciences, Inc.
|
Sponsored by
|
| There
is a need for a robust and sensitive multiplexed protein detection
system in a format that is familiar to and affordable for the typical
ELISA user. We have used a proprietary gold particle-enhanced silver
deposition technology, a transparent nitrocellulose film, and a
proprietary CCD-based detection instrument to develop a novel 96-well
protein array system to meet this need. The system uses a newly
developed transparent nitrocellulose-coated plastic substrate formatted
in standard microarray slide and 96-well format. Gold particle-enhanced
silver deposition enables robust multiplexed protein assays with
superior sensitivity compared to bead-based systems and
fluorescence-based microarrays. Silver deposition avoids problems
normally associated with colorimetric detection such as spot blooming
because it does not rely on enzymatic amplification. Each microplate
well can contain as many as several hundred highly localized array spots
that can be archived for years. Protein arrays and antibody arrays are
now being validated using this system for use in research and in
clinical testing environments. |
|
3:35 Refreshment Break in the Exhibit Hall
4:30 Detection of Autoimmune Disease by Serum Antibody Profiling Using Peptoid Microarrays
Muralidhar Reddy Moola, Ph.D., Assistant Professor, Department of Internal Medicine, University of Texas Southwestern Medical Center
The adaptive immune system reacts specifically with many different disease states. Unfortunately, there are many diseases for which antibodies and the antigens they recognize are unknown. In these cases, various approaches have been employed to screen large collections of proteins or other biomolecules such as proteome arrays, cDNA libraries, etc. in an attempt to discover antigens recognized by disease-specific antibodies. We have developed a technique for circumventing this problem that uses key concepts from the field of combinatorial chemistry. This methodology thus provides an unbiased method for the discovery of IgG serum biomarkers that does not require prior knowledge of native antigens. Our results, albeit from a simple animal model system, suggest that it should be possible to employ this approach to generally detect and monitor humoral immune responses using these small molecule microarrays.
5:00 Protein and Antibody Arrays in Biomarker Discovery and Development
Ruo-pan Huang, M.D., Ph.D., Founder/President, Raybiotech, Inc.
One key issue for biomarker discovery and development is to develop high-content assays for biomarker screen and robust assays for validation and clinical application. We have developed a new strategy to meet this demand. High-density of antibody arrays and protein arrays are used to profile protein expression, auto-antibody production and glycosylation in patients’ specimen. Through identification of unique biomarkers or biosignatures, quantitative antibody arrays can be developed for validation in large numbers of clinical samples. This talk will focus on using protein and antibody arrays for general biomarker screen and target protein validation.
5:30 Panel Discussion with Afternoon Speakers
6:00 Reception in the Exhibit Hall
7:00 Close of Day
Overview | Short
Courses | Day 1 |
Day 2 | Download Brochure
For more information, please contact:
Mary Ann Brown, Sr. Conference Director
Phone: 781-972-5497
E-mail: mabrown@healthtech.com
For exhibit and sponsorship information, please contact:
Suzanne Carroll, Manager-Business
Development
Phone: 781-972-5452
E-mail: scarroll@healthtech.com
|
